Xenothera Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
19
Xenothera General Information
Description
Developer of a glyco-humanized antibody platform designed to renovate immunological treatments. The company's platform allows the production of multispecific glyco-humanized polyclonal antibodies, which are effective, better tolerated, and applicable to a wide range of therapeutic indications, enabling medical professionals to address major unmet medical needs, especially in solid and liquid tumours.
Contact Information
Website
www.xenothera.comCorporate Office
- 21 Rue La Nouë Bras De Fer
- 44200 Nantes
- France
Corporate Office
- 21 Rue La Nouë Bras De Fer
- 44200 Nantes
- France
Xenothera Timeline
Xenothera Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Accelerator/Incubator | 01-May-2025 | Completed | Clinical Trials - Phase 2 | |||
| 9. Grant | 15-Jan-2025 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series B) | 29-Jun-2021 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC | 15-Jun-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Grant | 18-Mar-2020 | Completed | Clinical Trials - Phase 2 | |||
| 5. Early Stage VC | Completed | Clinical Trials - Phase 2 | ||||
| 4. Early Stage VC (Series A) | 21-Dec-2018 | Completed | Clinical Trials - Phase 2 | |||
| 3. Grant | 12-Dec-2016 | Completed | Startup | |||
| 2. Seed Round | 10-Jun-2016 | $2.25M | $3.26M | Completed | Startup | |
| 1. Seed Round | 17-Dec-2014 | $1.01M | $1.01M | Completed | Startup |
Xenothera Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 43,272 | $1.205492 | $55.72 | $55.72 | 1x | $55.72 | 21.16% | |
| Ordinary | 21,600 | $1.205492 | $45.21 | $45.21 | 1x | $45.21 | 10.56% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Xenothera Comparisons
Industry
Financing
Details
Xenothera Competitors (3)
One of Xenothera’s 3 competitors is Enterome, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enterome | Venture Capital-Backed | Paris, France | ||||
| Valerio Therapeutics | Formerly VC-backed | Paris, France | ||||
| MaaT Pharma | Formerly VC-backed | Lyon, France |
Xenothera Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Xenothera Patents
Xenothera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4722240-A1 | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers and compositions thereof | Pending | 07-Oct-2024 | ||
| WO-2026077854-A1 | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers and compositions thereof | Pending | 07-Oct-2024 | ||
| AU-2024356118-A1 | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers | Pending | 04-Oct-2023 | ||
| EP-4788371-A1 | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers | Pending | 04-Oct-2023 | ||
| WO-2025073856-A1 | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers | Inactive | 04-Oct-2023 | C07K16/28 |
Xenothera Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Xenothera Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlanpole | Accelerator/Incubator | |||
| France 2030 | Government | |||
| Anaxago | Real Estate | Minority | ||
| CapHorn Invest | Venture Capital | Minority | ||
| Angel (individual) | Minority |
Xenothera FAQs
-
When was Xenothera founded?
Xenothera was founded in 2014.
-
Where is Xenothera headquartered?
Xenothera is headquartered in Nantes, France.
-
What is the size of Xenothera?
Xenothera has 23 total employees.
-
What industry is Xenothera in?
Xenothera’s primary industry is Drug Discovery.
-
Is Xenothera a private or public company?
Xenothera is a Private company.
-
What is Xenothera’s current revenue?
The current revenue for Xenothera is .
-
How much funding has Xenothera raised over time?
Xenothera has raised $52.5M.
-
Who are Xenothera’s investors?
Atlanpole, France 2030, Anaxago, CapHorn Invest, and are 5 of 19 investors who have invested in Xenothera.
-
Who are Xenothera’s competitors?
Enterome, Valerio Therapeutics, and MaaT Pharma are competitors of Xenothera.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
